Wave Life Sciences’ Price Target Raised to $50 After WVE-006 Rights Transfer
Wave Life Sciences secured Buy ratings from all 15 covering analysts, with a median one-year price target of $32.57, implying more than 154% upside. Clear Street’s William Maughan raised his target from $47 to $50 (291% upside) after GlaxoSmithKline transferred WVE-006 rights for alpha-1 antitrypsin deficiency.
1. Analyst Coverage and Price Targets
Wave Life Sciences is covered by 15 analysts, all rating it Buy, with a current median one-year price target of $32.57, reflecting over 154% upside from current levels.
2. Clear Street Upgrade and Price Increase
On February 2, Clear Street’s William Maughan reiterated his Buy rating and raised his price target for Wave Life Sciences from $47 to $50, implying approximately 291% upside for shareholders.
3. WVE-006 Rights Transfer
GlaxoSmithKline transferred global development and commercialization rights for WVE-006, Wave’s alpha-1 antitrypsin deficiency candidate, strengthening the company’s control over this program and validating its RNA editing platform.
4. Pipeline and Technology Platform
Wave leverages its PRISM stereopure oligonucleotide platform across a pipeline that includes WVE-006, WVE-007 and WVE-N531, with WVE-007 remaining the most significant value driver in upcoming clinical milestones.